TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Launched by TEMPUS AI · Jan 5, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The TEMPUS ARIES study is a research project looking at how certain cancer markers in the blood can help us understand and improve cancer care. Participants in this study will undergo regular blood tests to check for these markers, known as ctDNA, while they receive their usual cancer treatments. This study is open to anyone aged 18 and older who has been diagnosed with cancer and is willing to participate. However, individuals who cannot have additional blood samples taken will not be eligible.
If you decide to join the trial, you will be asked to provide blood samples at specific times during your treatment. Your participation will help researchers learn more about cancer and potentially lead to better ways to monitor and treat the disease. This study is currently recruiting participants, and everyone, regardless of gender, is welcome to join. Your involvement could make a difference in the future of cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ≥18 years of age
- • 2. Willing to participate in the research
- • 3. Able to provide informed consent
- • 4. Must be diagnosed with cancer
- Exclusion Criteria:
- • 1. Not willing or able to have additional blood samples collected
About Tempus Ai
Tempus AI is a leading technology company at the forefront of precision medicine, specializing in harnessing the power of data and artificial intelligence to advance cancer care. By integrating clinical and molecular data with advanced analytics, Tempus AI empowers healthcare providers to make informed, evidence-based decisions that enhance patient outcomes. With a commitment to innovation and collaboration, Tempus AI drives the development of targeted therapies and personalized treatment plans, positioning itself as a pivotal force in the evolution of oncology and clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Peoria, Illinois, United States
Goshen, Indiana, United States
Reno, Nevada, United States
Jacksonville, Florida, United States
York, Pennsylvania, United States
Ithaca, New York, United States
East Syracuse, New York, United States
Las Vegas, Nevada, United States
Fairhaven, Massachusetts, United States
Atlanta, Georgia, United States
Springfield, Missouri, United States
Rio Piedras, , Puerto Rico
Fort Wayne, Indiana, United States
Rolling Meadows, Illinois, United States
Hinsdale, Illinois, United States
Hannibal, Missouri, United States
Norwich, Connecticut, United States
Belleville, New Jersey, United States
Maumee, Ohio, United States
O'fallon, Illinois, United States
Osage Beach, Missouri, United States
Birmingham, Alabama, United States
Carterville, Illinois, United States
Springfield, Illinois, United States
Morehead, Kentucky, United States
Belleville, New Jersey, United States
Frederick, Maryland, United States
Fargo, North Dakota, United States
Whittier, California, United States
Patients applied
Trial Officials
Michelle Ting-Lin, MD
Study Director
Tempus AI, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported